p-Index From 2021 - 2026
0.408
P-Index
This Author published in this journals
All Journal Heart Science Journal
Claim Missing Document
Check
Articles

Found 2 Documents
Search

A review of RUNX2 genetic interactions and their role in cardiovascular disease Christine, Anastasia; Rohman, Mohammad Saifur; Yogibuana, Valerinna
Heart Science Journal Vol. 7 No. 2 (2026): The Evolving Landscape of Heart Failure
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.02.5

Abstract

Cardiovascular diseases (CVD) remain the leading cause of global mortality, with underlying factors such as genetics, environment, and lifestyle interacting in complex and multiple ways. Runt-related transcription factor 2 (RUNX2), traditionally associated with osteogenesis, has gained recognition for its critical role in cardiovascular health. RUNX2 contributes to vascular calcification (VC), endothelial dysfunction, and myocardial fibrosis, thereby accelerating CVD progression. Its expression is influenced by multiple upstream regulators relevant to vascular pathology, such as BMP2/SMAD, Wnt/β-catenin, and ERK signaling, along with epigenetic mechanisms and gene-environment interactions such as oxidative stress, hyperglycemia, and dyslipidemia. Genetic variants in RUNX2 and environmental variables including diet and physical inactivity, amplify its activation, worsening VC and cardiovascular risk. RUNX2 reduces endothelial nitric oxide bioavailability, enhances vascular inflammation, and activates profibrotic signaling in cardiac tissue, promoting vascular dysfunction and myocardial remodeling. Circulating RUNX2 levels and genetic variations exhibit potential as diagnostic and predictive indicators for cardiovascular disease. Severalpharmaceutical agents including metformin, empagliflozin, and statins,   as well as natural substances such green tea polyphenols and green coffee extract, have demonstrated partial modulatory effects on RUNX2 activity. Moreover, genome-editing tools such as CRISPR-Cas9 present future opportunities for selective RUNX2 targeting. Comprehensive understanding of RUNX2 regulation and its interaction with genetic and environmental factors offers novel opportunities for personalized CVD prevention and treatment approaches through lifestyle modification, pharmacotherapy, and gene-based interventions in the future.
Effects of metformin and empagliflozin on runt- related transcription factor-2 (RUNX2) mRNA expression in vascular calcification of metabolic syndrome rats Christine, Anastasia; Rohman, Mohammad Saifur; Yogibuana, Valerinna
Heart Science Journal Vol. 7 No. 4 (2026): Navigating High-Risk Cardiovascular Subsets: Premature Disease, Plaque Complexi
Publisher : Universitas Brawijaya

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.hsj.2026.007.04.5

Abstract

Background: Vascular calcification (VC) is a severe vascular complication of metabolic syndrome (MetS), strongly correlated with increased cardiovascular morbidity and mortality. One of the most important regulator of osteoblastic differentiation, runt-related transcription factor-2 (RUNX2) has a crucial role in VC by promoting the transformation of vascular smooth muscle cells (VSMCs) toward an osteoblast-like phenotype.Objective: This study explored the effect of MetS on VC by raising RUNX2 mRNA expression and how metformin and empagliflozin affect RUNX2 mRNA expression in MetS-induced rats.Methods:  Twenty Sprague-Dawley male rats were randomly separated into four groups: negative control (NC), MetS, MetS treated with metformin 500 mg/kgBW/day, and MetS treated with empagliflozin 30 mg/kgBW/day. MetS was induced by a high-fat high-sucrose diet and low-dose streptozotocin injection. RUNX2 mRNA expression was measured using RT-PCR and aortic tissue was stained using hematoxylin-eosin.Result: MetS induction resulted in visible microcalcification within the aortic wall and significantly increased RUNX2 mRNA expression compared with the NC group (mean ± SD: 38 ± 15, p = 0.01), indicating enhanced VC. Metformin markedly reduced RUNX2 mRNA expression (mean ± SD: 73 ± 7, p = 0.03), whereas empagliflozin showed a non-significant decrease (mean ± SD: 76 ± 23, p = 0.87). Conclusion: MetS induction can stimulate VC accompanied by increased RUNX2 mRNA expression in rats aortic tissue. Metformin and empagliflozin mitigate these changes, with metformin showing a more pronounced effect. This strengthens the importance of controlling MetS to reduce the risk of VC.